Jefferies Group LLC Galectin Therapeutics Inc Transaction History

Jefferies Group LLC

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2019 Aug 14, 2019	SELL	$3.61 - $5.0 $96,748 - $134,000	-26,800 Closed	0 $0
Q1 2019 May 15, 2019	BUY	$3.86 - $6.02 $103,448 - $161,336	26,800 New	26,800 $137,000
Q2 2018 Aug 14, 2018	SELL	$3.16 - $9.16 $63,200 - $183,200	-20,000 Closed	0 $0
Q1 2018 May 15, 2018	BUY	$3.78 - $5.97 $75,600 - $119,400	20,000 New	20,000 $95,000

10M

1.16M

1.98M

Ticker GALT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 59,426,000
Market Cap $73.7M
Description
Galectin Therapeutics Inc., a clinical stage biopharmaceutical company, engages in the research and development of therapies for fibrotic, cancer, and other diseases. The company's lead product candidate is belapectin (GR-MD-02) galectin-3 inhibitor, a galactoarabino-rhamnogalacturonan polysaccharide polymer that is in Phase III clinical trial f...

Get notified when there are updates to the investment portfolio of Jefferies Group LLC, based on Form 13F filings with the SEC.

Stay updated on Jefferies Group LLC with notifications on news.